Vor Bio has completed enrollment in its Phase 3 UPSTREAM MG trial for telitacicept, a drug targeting autoimmune diseases like generalized myasthenia gravis (gMG). The company expects topline results in the first half of 2027 and plans to start a Phase 3 trial for ocular myasthenia gravis (oMG) in the same period. Enrollment continues for a Phase 3 trial in primary Sjögren’s disease. With $481.6 million in cash, Vor Bio is well-funded through early 2029 to advance its clinical programs. These developments position telitacicept as a promising dual BAFF/APRIL inhibitor with potential regulatory approvals in major markets.
Vor Bio's recent corporate update comes as Pluang's health sector shows mixed performance. For readers following health stocks, here is Pluang's market snapshot as of Oct 30, 2026 18:43 WIB: out of 150 priced health-sector US stocks, 71 rose and 72 fell. Notable movers include Twist Bioscience Corp (TWST) at USD 161.99 with a 1-day change of -6.61% and a typical hold time of 27 days, BrightSpring Health Services Inc. (BTSG) at USD 64.06 up 6.38% with a 10-day hold time, and 10X Genomics Inc (TXG) at USD 76.56 down 6.12% with a 92-day hold time.
FreightCar America disclosed on October 19, 2026, that it removed 1,285 railcars from its backlog after a customer was unlikely to fulfill contractual obligations, causing its stock to drop 31.4% to $4.02. This sharp decline has led Glancy Prongay Wo...
FirstCash Holdings, Inc. shares fell 14.75% following the October 22, 2026 disclosure of its third quarter financial results, which showed a 28% year-over-year decline in operating income for its American First Finance segment to $33 million. The com...
The global screw compressors market is projected to grow from $13.97 billion in 2026 to $18.38 billion by 2031, at a CAGR of 5.66%. Growth is fueled by rising industrial automation, energy-efficiency regulations, and demand in manufacturing, oil and ...
Enova International's stock fell 23.43% after the company withdrew its application to acquire Grasshopper Bancorp and become a bank holding company. The withdrawal was due to unclear regulatory standards and political pressures cited by Enova. This s...
The global dialysis machines market is forecasted to grow from $17.89 billion in 2026 to $31.54 billion by 2035, at a CAGR of 6.5%. Growth is fueled by rising chronic kidney disease cases, expanding dialysis infrastructure, and innovations like home ...
